Table 2 Imaging and Ki-67 results, n = 40
Aromatase inhibitor ( n = 28) | Trastuzumab ( n = 12) | |||
|---|---|---|---|---|
n (%) | Median (min, max) | n (%) | Median (min, max) | |
SUVmax of index lesion at baseline | 28 | 4.6 (1.6, 18.9) | 12 | 8.9 (2.6, 17.2) |
Days between FDG PET scans | 28 | 18 (12, 33) | 12 | 15 (13, 29) |
SUVmax of index lesion at follow-up | 28 | 3.2 (1.2, 13.6) | 12 | 5.3 (1.6, 17.1) |
Percent change in SUVmax | 28 | −28 (−60, 11) | 12 | −25 (−75, 9) |
Patients with FDG PET early response (≥20% SUV decline) | 20 (71%) | 6 (50%) | ||
Ki-67 prior to run-in therapy (%) | 22 | 15 (<5, 41) | 5 | 40 (5, 60) |
Days between successful biopsies | 14 | 51 (16, 608) | 3 | 29 (14, 49) |
Ki-67 following run-in therapy (%) | 14 | 5 (0.5, 60) | 3 | 25 (20, 60) |
Patients with Ki-67 ≤5% following run-in therapy | 11 (79%) | 0 (0%) | ||
Change in Ki-67 | 14 | −8 (−26, 30) | 3 | 0 (−15, 15) |